Influence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study

Simple item page
dc.catalogadorjca
dc.contributor.authorMondaca Contreras, Sebastián Patricio
dc.contributor.authorWalbaum, Benjamín
dc.contributor.authorCorre, Nicole Le
dc.contributor.authorFerrés Garrido, Marcela Viviana
dc.contributor.authorValdés, Alejandro
dc.contributor.authorMartínez-Valdebenito, Constanza
dc.contributor.authorRuiz-Tagle, Cinthya
dc.contributor.authorMacanas Pirard, Patricia
dc.contributor.authorRoss, Patricio
dc.contributor.authorCisternas, Betzabé
dc.contributor.authorPérez, Patricia
dc.contributor.authorCabrera, Olivia
dc.contributor.authorCerda, Valentina
dc.contributor.authorOrmazábal, Ivana
dc.contributor.authorBarrera Vásquez, Aldo Vincen
dc.contributor.authorPrado, María E.
dc.contributor.authorVenegas, María I.
dc.contributor.authorPalma, Silvia
dc.contributor.authorBroekhuizen, Richard
dc.contributor.authorKalergis, Alexis
dc.contributor.authorBueno, Susan M.
dc.contributor.authorEspinoza, Manuel A.
dc.contributor.authorBalcells Marty, María Elvira
dc.contributor.authorNervi Nattero, Bruno
dc.date.accessioned2023-07-11T15:02:09Z
dc.date.available2023-07-11T15:02:09Z
dc.date.issued2023
dc.description.abstractCancer patients on chemotherapy have a lower immune response to SARS-CoV-2 vaccines. Therefore, through a prospective cohort study of patients with solid tumors receiving chemotherapy, we aimed to determine the immunogenicity of an mRNA vaccine booster (BNT162b2) among patients previously immunized with an inactivated (CoronaVac) or homologous (BNT162b2) SARS-CoV-2 vaccine. The primary outcome was the proportion of patients with anti-SARS-CoV-2 neutralizing antibody (NAb) seropositivity at 8–12 weeks post-booster. The secondary end points included IgG antibody (TAb) seropositivity and specific T-cell responses. A total of 109 patients were included. Eighty-four (77%) had heterologous vaccine schedules (two doses of CoronaVac followed by the BNT162b2 booster) and twenty-five had (23%) homologous vaccine schedules (three doses of BNT162b2). IgG antibody positivity for the homologous and heterologous regimen were 100% and 96% (p = 0.338), whereas NAb positivity reached 100% and 92% (p = 0.13), respectively. Absolute NAb positivity and Tab levels were associated with the homologous schedule (with a beta coefficient of 0.26 with p = 0.027 and a geometric mean ratio 1.41 with p = 0.044, respectively). Both the homologous and heterologous vaccine regimens elicited a strong humoral and cellular response after the BNT162b2 booster. The homologous regimen was associated with higher NAb positivity and Tab levels after adjusting for relevant covariates.
dc.fechaingreso.objetodigital2023-07-11
dc.fuente.origenORCID
dc.identifier.doi10.3390/vaccines11071193
dc.identifier.isbn0899-4056
dc.identifier.urihttps://doi.org/10.3390/vaccines11071193
dc.identifier.urihttps://www.mdpi.com/2076-393X/11/7/1193
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/74161
dc.information.autorucEscuela de Medicina; Mondaca Contreras, Sebastián Patricio; 0000-0002-1130-0370; 190152
dc.information.autorucEscuela de Medicina; Walbaum, Benjamín; 0000-0003-2314-5360; 163702
dc.information.autorucEscuela de Medicina; Macanas Pirard, Patricia; 0000-0003-2631-8618; 1006859
dc.information.autorucEscuela de Medicina; Nervi Nattero, Bruno; 0000-0002-3016-7261; 604
dc.information.autorucEscuela de Medicina; Ferrés Garrido, Marcela Viviana; 0000-0001-9415-4657; 66180
dc.information.autorucFacultad de Ciencias Biológicas; Barrera Vásquez, Aldo Vincen; S/I; 1031200
dc.information.autorucEscuela de Medicina; Balcells Marty, María Elvira; 0000-0002-7223-9665; 7462
dc.issue.numero7
dc.language.isoen
dc.nota.accesoContenido completo
dc.pagina.final12
dc.pagina.inicio1
dc.revistaVaccines
dc.rightsacceso abierto
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleInfluence of SARS-CoV-2 mRNA Vaccine Booster among Cancer Patients on Active Treatment Previously Immunized with Inactivated versus mRNA Vaccines: A Prospective Cohort Study
dc.typeartículo
dc.volumen11
sipa.codpersvinculados190152
sipa.codpersvinculados163702
sipa.codpersvinculados1006859
sipa.codpersvinculados604
sipa.codpersvinculados66180
sipa.codpersvinculados1031200
sipa.codpersvinculados7462
sipa.trazabilidadORCID;2023-07-10
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
vaccines-11-01193.pdf
Size:
0 B
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas